Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,
Go back to Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 161.02 -1.69 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $162.71 | 52 Week High | $58.46 | |||
| Open | $162.04 | 52 Week Low | $31.25 | |||
| Day High | $162.97 | P/E | N/A | |||
| Day Low | $160.18 | EPS | $-0.69 | |||
| Volume | 331,683 | |||||
